Claims for Patent: 8,592,434

Summary for Patent: 8,592,434

Title:	Mucoadhesive buccal tablets for the treatment of orofacial herpes
Abstract:	The present invention relates to the treatment or prevention of mucocutaneous herpes simplex virus diseases using prolonged release mucoadhesive buccal tablets comprising an acyclic guanosine antiviral agent. These tablets are particularly suitable for the treatment or prevention of orofacial herpes.
Inventor(s):	Attali; Pierre (Vincennes, FR), Costantini; Dominique (Paris, FR), Lemarchand; Caroline (Paris, FR)
Assignee:	BioAlliance Pharma SA (Paris, FR)
Application Number:	12/634,225
Patent Claims:	1. A method for treating orofacial herpes comprising administering to a patient suffering from orofacial herpes only a single dose of a prolonged release mucoadhesive buccal tablet comprising: 50 to 200 mg of acyclovir, 1 to 75% by weight of a diluent, 1 to 10% by weight of an alkali metal alkylsulfate, 0.1 to 5% by weight of a binding agent, 5 to 80% by weight of natural milk proteins, and 5% to 80% by weight of at least one hydrophilic polymer that provides a sustained release of acyclovir. 2. The method of claim 1, wherein the acyclovir is present in an amount of 50 mg. 3. The method of claim 1, wherein the mucoadhesive buccal tablet comprises: (a) 2 to 6% by weight of an alkali metal alkylsulfate, (b) 0.1 to 5% by weight of a binding agent, (c) 10 to 40% by weight of natural milk proteins and (d) 10% to 40% by weight of at least one hydrophilic polymer that provides a sustained release of acyclovir. 4. The method of claim 3, wherein the alkali metal alkylsulfate is sodium lauryl sulfate. 5. The method of claim 3, wherein at least one hydrophilic polymer that provides a sustained release of acyclovir is hydroxypropylmethyl cellulose. 6. The method of claim 3, wherein said natural milk proteins comprise milk protein concentrate. 7. The method of claim 3, wherein the acyclovir is present in an amount of 50 mg. 8. The method of claim 1, wherein the mucoadhesive buccal tablet comprises: (a) 50 mg acyclovir, (b) 15% by weight microcrystalline cellulose, (c) 4.5% by weight sodium lauryl sulfate, (d) 0.4% by weight polyvinylpyrrolidone, (e) 20% by weight milk protein concentrate, and (f) 15% by weight hydroxypropylmethyl cellulose. 9. The method of claim 1, wherein said patient is suffering from nonvesicular symptoms of orofacial herpes. 10. The method of claim 8, wherein said patient is suffering from nonvesicular symptoms of orofacial herpes. 11. The method of claim 1, wherein said patient is immunocompetent. 12. The method of claim 8, wherein said patient is immunocompetent. 13. The method of claim 1, wherein said patient is suffering from recurrent orofacial herpes. 14. The method of claim 8, wherein said patient is suffering from recurrent orofacial herpes. 15. The method of claim 1, wherein said mucoadhesive buccal tablet is effective to reduce the duration of orofacial herpes episodes. 16. The method of claim 1, wherein said mucoadhesive buccal tablet is effective to delay the recurrence of orofacial herpes episodes. 17. The method of claim 1, wherein said mucoadhesive buccal tablet is effective to increase the occurrence of aborted episodes of orofacial herpes. 18. The method of claim 1, wherein said natural milk proteins comprise milk protein concentrate. 19. The method of claim 1, wherein said natural milk proteins comprise total milk proteins. 20. The method of claim 3, wherein at least one hydrophilic polymer that provides a sustained release of acyclovir is a polysaccharide. 21. The method of claim 20, wherein at least one hydrophilic polymer that provides a sustained release of acyclovir is a cellulose-based polymer. 22. The method of claim 21, wherein at least one hydrophilic polymer that provides a sustained release of acyclovir is a cellulose ether.